IRCCS Azienda Ospedaliero-Universitaria di Bologna
OSAS is a syndrome characterized by the partial or total collapse of the high airways which determines snore, airflow limitation, hypopnea and apnea.These events cause desaturations, daytime sleepiness and an increased risk of cardio and cerebral vascular diseases.
OSAS's prevalence is estimated between 64-83% among patients affected by resistant arterial hypertension; therefore OSAS's screening is mandatory during the clinical work-up of these patients.
This study is a randomized, interventional, spontaneous, exploratory, cross-over and monocentric trial, which assesses the utility and reliability of the reduced cardio-respiratory monitoring (type IV portable monitoring: Somnocheck micro Weinmann) to estimate the prevalence of OSAS among patients affected by resistant systemic arterial hypertension. The results are compared with a complete cardio-respiratory monitoring (type III portable monitoring: Somnocheck 2 Weinmann).
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Resistant Arterial Hypertension
Patients must sign the informed consent
You may not be if
atrial fibrillation with haemodynamic instability
congestive hearth failure,
BMI\>45 kg/m2,
respiratory failure
renal or liver failure,
stroke,
implantable cardioverter-defibrillator (ICD),
pacemaker (PM),
previous diagnosis of OSAS,
pregnancy,
breastfeeding,
patients must not be already enrolled in other clinical trial.